Skip to main content

Advertisement

SpringerLink
Log in

Assessing the cost-effectiveness of pharmacogenomics

  • Published:
AAPS PharmSci Aims and scope Submit manuscript

Abstract

The use of pharmacogenomics to individualize drug therapy offers the potential to improve drug effectiveness, reduce adverse side effects, and provide cost-effective pharmaceutical care. However, the combinations of disease, drug, and genetic test characteristics that will provide clinically useful and economically feasible therapeutic interventions have not been clearly elucidated. The purpose of this paper was to develop a framework for evaluating the potential cost-effectiveness of pharmacogenomic strategies that will help scientists better understand the strategic implications of their research assist in the design of clinical trials, and provide a guide for health care providers making reimbursement decisions. We reviewed concepts of cost-effectiveness analysis and pharmacogenomics and identified 5 primary characteristics that will enhance the cost-effectiveness of pharmacogenomics: 1) there are severe clinical or economic consequence that are avoided through the use of pharmacogenomics, 2) monitoring drug response using current methods is difficult, 3) a well-established association between genotype and clinical phenotype exists, 4) there is a rapid and relatively inexpensive genetic test, and 5) the variant gene is relatively common. We use this framework to evaluate several examples of pharmacogenomics. We found that pharmacogenomics offers great potential to improve patients' health in a cost-effective manner. However, pharmacogenomics will not be applied to all currently marketed drugs, and careful evaluations are needed on a case-by-case basis before investing resources in research and development of pharmacogenomic-based therapeutics and making reimbursement decisions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Collins FS. Genetics: An explosion of knowledge is transforming clinical practice. Geriatrics. 1999;54:41–47.

    CAS  PubMed  Google Scholar 

  2. Friend SH, How DNA microarrays and expression profiling will affect clinical practice. BMJ 1999;319:1–2.

    Article  Google Scholar 

  3. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999; 286:487–491.

    Article  CAS  PubMed  Google Scholar 

  4. Brookes AJ. The essence of SNPs. Gene 1999;234:177–186.

    Article  CAS  PubMed  Google Scholar 

  5. Gelehrter TD, Collins FS, Ginsburg D. Principles of Medical Genetics. 2nd ed. Baltimore, Md: Williams & Wilkins, 1998.

    Google Scholar 

  6. McCarthy JJ, Hilfiker R. The use of single-nucleotide polymorphism maps in pharmacogenomics. Nat Biotechnol. 2000;18:505–508.

    Article  CAS  PubMed  Google Scholar 

  7. Veenstra DL, Kollman PA. Modeling protein stability a theoretical analysis of the stability of T4 lysozyme mutants. Protein Eng. 1997;10:789–807.

    Article  CAS  PubMed  Google Scholar 

  8. Sadee W. Pharmacogenomics. BMJ. 1999;319:1–4.

    Article  Google Scholar 

  9. Marshall A. Getting the right drug into the right patient. Nat Biotechnol. 1997;15:1249–1252.

    Article  CAS  PubMed  Google Scholar 

  10. Kleyn PW, Vesell ES. Genetic variation as a guide to drug development. Science. 1998;281:1820–1821.

    Article  CAS  PubMed  Google Scholar 

  11. Hodgson J, Marshall A. Pharmacogenomics: will the regulators approve? Nat Biotechnol. 1998;16:243–246.

    Article  CAS  PubMed  Google Scholar 

  12. Regalado A. Inventing the pharmacogenomics busines. Am J Health Syst Pharm. 1999;56:40–50.

    CAS  PubMed  Google Scholar 

  13. Persidis A. The business of pharmacogenomics. Nat Biotechnol 1998;16:209–210.

    Article  CAS  PubMed  Google Scholar 

  14. Garber AM, Phelps CE. Economic foundations of cost-effectiveness analysis. J Health Econ. 1997;16:1–31.

    Article  CAS  PubMed  Google Scholar 

  15. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276:1253–1258.

    Article  CAS  PubMed  Google Scholar 

  16. Drummond M, Dubois D, Garattini L. et al. Current trends in the use of pharmacoecoinomics and outcomes research in Europe. Value in Health. 1999;2:323–332.

    Article  CAS  PubMed  Google Scholar 

  17. CCOHTA. Canadian Coordinating Office for Health Technology Assessment Guidelines for economic evaluations of pharmacoenticals. Canada. 2nd ed. 1997 (http://www.ccohta.ca/main-e.html).

  18. Mather DB, Sullivan SD, Augenstein D, Fullerton DS, Athlerly D. Incorporating clinical outcomes and economic consequences into drug formulary decisions: a practical approach. Am J Manag Care. 1999;5:277–285.

    CAS  PubMed  Google Scholar 

  19. Kuivenhoven JA, Jukema JW, Zwinderman AH, de Knijf P. McPherson R, Bruschke AV, Lie KI, Kastelein JJ. The role of a common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med. 1998;338:86–93.

    Article  CAS  PubMed  Google Scholar 

  20. McHutchinson JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustigi VK, Goodman ZD, Ling M, Cort S, Albrecht JK. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitic C. N Engl J Med 1998;339(21):1485–1492.

    Article  Google Scholar 

  21. Younossi ZM, Singer ME, McHutchison JG, Shermock KM. Costeffectiveness of interferon alpha2b combined with ribavirin for the treatment of chronic hepatitis C. Hepatology. 1999;30(5):1318–1324.

    Article  CAS  PubMed  Google Scholar 

  22. Veenstra DL, Tran C, Lum B, Cheung R. The cost-effectiveness of genetic screening and combination theapy for hepatitis C. Paper presented at: Drug Information Association 2nd Annual Workshop on Pharmacentical Outcomes Research. May 11–12. 2000: Seattle, Wash.

  23. Weinstein MC, Goldie SJ, Cohen C, Losian H, Zhang HJ, Kimmel AD. Resistance testing to guide the choice of second-line. antitretroviral therapy in HIV: clinical impact and cost-effectiveness [abstract]. In: Program and Abstracts of the meeting of the Sciety for Medical Decision Making: October 3–6, 1999: Reno. Nev.

  24. Anis AH, Wang X, Harrigan R. Hogg RS, Yin B. O'Shaghnessy MV, Schlechter MT, Montaner JSG. Optimizing drug treatment cost-effectiveness analysis of HIV/AIDS drug resistance testing [abstract]. In: Program and Abstracts of the Meeting of the Society. for Medical Decision Making. October 3–6, 1999; Reno. Nev

  25. Shak S and the Herceptin Multinational Investigator Study Group Overview of the trastuzumab Herceptin) anti-HER2 monoclonal antibody clinical program in HER2-overexpressing metastatic breast cancer Semin Oncol. 1999;26(4 suppl 12):71–77.

    CAS  PubMed  Google Scholar 

  26. Motulsky AG. Drug reactions, enzymes and biochemical genetics. JAMA 1957;165:835–837.

    Article  CAS  Google Scholar 

  27. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9 Pharmacogenetics. 1994;4:39–42.

    Article  CAS  PubMed  Google Scholar 

  28. Aithal GP, Day CP, Kesteven PJ, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 1999;353:717–719.

    Article  CAS  PubMed  Google Scholar 

  29. Krynetski EY, Evans WE. Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm. Pharm Res. 1999;16(3):342–349.

    Article  CAS  PubMed  Google Scholar 

  30. Evans WE, Horner M, Chu YQ, Kalwinsky D, Roberts WM. Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia. J. Pediatr. 1991;119:985–989.

    Article  CAS  PubMed  Google Scholar 

  31. Lennard L, Gibson BE, Nicole T, Lilleyman JS. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine toxicity during treatment for acute lymphoblastic leukaemia. Arch Dis Child 1993;69:577–579.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  32. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther. 1989;46:149–154.

    Article  CAS  PubMed  Google Scholar 

  33. Detsky AS, Naglie G, Krahn MD, Naimark D, Redelmeier DA. Primer on medical decision analysis: Part 1—Getting started. Med Decis Making 1997;17:123–125.

    Article  CAS  PubMed  Google Scholar 

  34. Steinbach G, Lynch PM, Phillips RKS. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946–1952.

    Article  CAS  PubMed  Google Scholar 

  35. Perrin L, Telenti A. HIV treatment failure: testing for HIV resistance in clinical practice. Science. 1998; 280:1871–1873.

    Article  CAS  PubMed  Google Scholar 

  36. Richman DD. Principles of HIV resistance testing and overview of assay performance characteristics. Antivir Ther. 2000;5:27–31.

    CAS  PubMed  Google Scholar 

  37. Liggett SB. Phamacogenetics of relevant targets in asthma. Clin Exp Allergy. 1998;28(suppl 1):77–79.

    Article  CAS  PubMed  Google Scholar 

  38. Israel E, Drazen JM, Ligget SB, et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med. 2000;162:75–80.

    Article  CAS  PubMed  Google Scholar 

  39. Richard F, Helbecque N, Neuman E, Guez D, Levy R, Amouyel P. APOE genotyping and response to drug treatment in Alzheimer's disease. Lancet 1997;349:539.

    Article  CAS  PubMed  Google Scholar 

  40. Farlow MR, Lahiri DK, Poirier J, Davignon J, Hui S. Apolipoprotein E genotype and gender influence response to tacrine therapy. Ann N Y Acad Sci. 1996;802:101–110.

    Article  CAS  PubMed  Google Scholar 

  41. Jonsson EG, Nothen MM, Gustavsson JP, Neidt H, Bunzel R, Propping P, Sedvall GC. Polymorphisms in the dopamine, serotonin, and norepinephrine transporter genes and their relationships to monoamine metabolite concentrations in CSF of healthy volunteers. Psychiatry Res 1998; 79: 1–9.

    Article  CAS  PubMed  Google Scholar 

  42. Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA 1999;282:790–795.

    Article  CAS  PubMed  Google Scholar 

  43. Lichter JB, Kuith JH. The impact of pharmacogenetics on the future of healthcare. Curr Opin Biotechnol 1997;8:692–695.

    Article  CAS  PubMed  Google Scholar 

  44. Rioux PP. Clinical trials in pharmacogenetics and pharmacogenomics methods and applications. Am J Health Syst Pharm. 2000;57:887–898.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pharmacy, Pharmaceutical Outcomes Research and Policy Program and Public Health Genetics Program, University of Washington, Health Sciences Bldg., Room H-375A, Box 357630, 98195, Seattle, WA, USA

    David L. Veenstra & Mitchell K. Higashi

  2. Department of Clinical Pharmacy and Institute for Health Policy Studies, University of California-San Francisco, San Francisco, CA, USA

    Kathryn A. Phillips

Authors
  1. David L. Veenstra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mitchell K. Higashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kathryn A. Phillips
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David L. Veenstra.

Additional information

Published: September 14, 2000

Rights and permissions

Reprints and permissions

About this article

Cite this article

Veenstra, D.L., Higashi, M.K. & Phillips, K.A. Assessing the cost-effectiveness of pharmacogenomics. AAPS PharmSci 2, 29 (2000). https://doi.org/10.1208/ps020329

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1208/ps020329

Keywords

Search

Navigation